EphMRA Committee Telephone Meeting: Minutes & Actions 27 May 2020				
Participants	Mattias Blomgren	Camilla Ravazolla		
	Matteo Cappai	Bernadette Rogers		
	Florence Chopin	Jessica Santos		
	Jeanette Kaufmann	Matteo Scaringi		
	Roni DasGupta	Piergiorgio Ross		
	Xander Raijmakers			
Apologies	Alex Adams	Karen Giorgio Vigo		
	Anne Beatrice Clidassou	Analia Revaux		
	Christine May			
Please kindly remember that all EC discussions should remain confidential				

MINUTES & ACTIONS				
	Торіс	Action		
1	Introductions and apologies.			
2	AER Guidelines			
	No further feedback on AER guidelines.			
	France	Analia to		
	Query French guidance on disclosure of name of client (company). What impact will this have on PV? Analia is following up and will update EC as soon as possible (Covid-related issues slowing everything down).	follow up re: French national guidance		
	Germany	Suldance		
	Question on transfer of personal data in Germany. Not directly PV-related but rather the Code. EphMRA's Code states that ADM does not allow personal data to be transferred to the sponsor.			
	ADM is firm this is not what is stated in their guidelines. ADM allows personal data to be passed to the sponsor client provided it remains anonymised, secure and consent obtained. The respondent cannot consent to waive anonymity, i.e. data must remain anonymised. ADM review started to review their guidelines with the introduction of GDPR. The review is ongoing – guidelines to be updated.	Camilla		
	Agreed that national guidelines supersede EphMRA's. Modify Code to reflect accurate position of ADM on transfer of personal data. Helpful clarification for AERs too.	provide clarification BR/GB follow-up		
3	Code Update			
	Camilla has updated the ode and it will be finalised for mid July for publication September 2020.			
	Key changes:			
	 Australia – new! Clear national guidelines align well with EphMRA Brazil – new Data Protection law adopted 2018 to come into force in Aug 2020. However, delays as congress continue debating the law and an additional factor is the impact of Covid-19. Put on hold inclusion in Code until clearer on implications for MR. 			

	 France – PV activities and obligations still requires clarification (AR to update EC). Additional points regarding Loi Bertrand and Loi Anti-Cadeaux acts. Camilla requested Analia's help to check if any updates or changes need to incorporate into Code. Japan – DP law introduced 2017 and strict 3-year review process. A few things have changed including on HCP interactions and fees. Camilla will probably add to the Code unless she feels it should be in the country specific information. Norway and Russia – couple of points for clarification. No major changes. UK – Code relates to updated BHBIA Code (Apr-20). No major changes. USA – complex due to lack of Federal law and differing state laws. California Consumer Protection Act is key for MR but challenging to include in the Code and not possible with the addition of multiple state regulations. Roni recommended to monitor state-by-state. Camilla confirmed that it is feasible to include hyperlinks to state updates. EC review by end June. EphMRA to publish updated Code Sep-20. 	Analia follow up LB/LAC acts & notify CR if any changes needed in Code update Camilla to include links to US state updates in Code. EC review by end June.
	Final comment Matteo regarding new advice on restrictions interviewing HCPs in public- facing healthcare roles in France. Similar advice as applying to Italian HCPs.	Matteo send info to BR to circulate to EC
4	Webinars Positive feedback and scores for the April Webinar on 'what's new'. It was agreed to hold a webinar for September to update members on 'what's new in the Code' and other developments, e.g. Loi Bertrand in France, Germany? EC agreed this.	BR set-up webinar for September 'what's new in the Code'
5	Update EDPB guidance Camilla confirmed joint EphMRA/ESOMAR/ BHBIA/ADM positioning paper representing the state and opinions of the MR sector submitted to the European Data Protection Supervisor (EDPS). The EDPS acknowledged receipt and pleased to have received the input. EDPS review of guidance for scientific research (most complex area and includes MR) is ongoing. Again, COVID-19 pandemic has slowed down the review. No indication of likely timeline of when EDPS will provide feedback or further guidance.	BR to add EDPS positioning paper on EphMRA site
6	AOB Next call is in September to discuss EC priorities for next year, i.e. starting Oct-20 through to Sep-21. Close meeting	BR send EC dates for next EC call